Febuxostat

Nature Reviews Drug Discovery

Volumn 8, Issue 3, 2009, Pages 191-192

  Pascual, Eliseo ^a   Sivera, Francisca ^a   Yasothan, Uma ^b   Kirkpatrick, Peter ^c  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b IQVIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENURIC; ALLOPURINOL; BENZBROMARONE; FEBUXOSTAT; OXIPURINOL; PLACEBO; PROBENECID; SULFINPYRAZONE; UNCLASSIFIED DRUG; URIC ACID; URICOSURIC AGENT;

ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; GOUT; HUMAN; HYPERURICEMIA; KIDNEY CLEARANCE; KIDNEY FUNCTION; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; URIC ACID BLOOD LEVEL;

CHRONIC DISEASE; DRUG APPROVAL; EUROPEAN UNION; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; THIAZOLES; XANTHINE OXIDASE;

EID: 61649092040     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2831     Document Type: Article

References (17)

1. Choi, H. K. et al. Pathogenesis of gout. Ann. Intern. Med. 143, 499-516 (2005).
2. Zhang, W. et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 65, 1312-1324 (2006).
3. Pascual, E. & Sivera, F. Therapeutic advances in gout. Curr. Opin. Rheumatol. 19, 122-127 (2007).
4. Okamoto, K. et al. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J. Biol. Chem. 278, 1848-1855 (2003).
5. Osada, Y. et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur. J. Pharmacol. 241, 183-188 (1993).
6. Komoriya, K. et al. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. Eur. J. Pharmacol. 250, 455-460 (1993).
7. European Medicines Agency (EMEA). European Public Assessment Report - Adenuric. EMEA web site [online], http://www.emea.europa.eu/humandocs/ PDFs/EPAR/adenuric/H-777-PI-en.pdf (2008).
8. Schumacher, H. R. Jr et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 59, 1540-1548 (2008).
9. Becker, M. A. et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 353, 2450-2461 (2005).
10. Pascual, E. & Sivera, F. The time required for disappearance of urate crystals from synovial fluid after successful hypouricemic treatment relates to the duration of gout. Ann. Rheum. Dis. 66, 1056-1058 (2007).
11. Perez-Ruiz, F. et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 47, 356-360 (2002).
12. Singh, J. et al. Quality of care for gout in the US needs improvement. Arthritis Rheum. 57, 822-829 (2007).
13. Mikuls, T. et al. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology 44, 1038-1042 (2005).
14. Reinders, M. K. et al. A randomised controlled trial on the efficacy and tolerability with dose-escalation of allopurinol 300-600 mg/ day versus benzbromarone 100-200 mg/day in patients with gout. Ann. Rheum. Dis. 16 Jul 2008 (doi:10.1136/ard.2008.091462).
15. IMS MIDAS (2007).
16. Febuxostat for the management of hyperuricaemia in patients with gout. National Institute for Health and Clinical Excellence web site [online], http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11830 (2008).
17. Hauber, A. Bear Sterns Equity Research Report (Bear Sterns, 22 Feb 2008).